Immune-stimulatory mAbs are currently being evaluated as antitumor agents. Although overall toxicity from these agents appears to be moderate, liver toxicities have been reported and are not completely understood. We studied the effect of systemic CD40 antibody treatment on myeloid cells in the spleen and liver. Na€ ve and tumor-bearing mice were treated systemically with agonistic anti-CD40 antibody. Immune cell subsets in the liver and spleen, serum transaminases, and liver histologies were analyzed after antibody administration. Nox2
Introduction
The TNF receptor family member CD40 is a stimulatory molecule constitutively expressed on a large variety of cells, including dendritic cells, B cells, macrophages, and endothelial cells (1) (2) (3) (4) (5) . CD40 engagement of antigen-presenting cells provides the "license" to T-cell help and enhances T-cell activation (6, 7) . Agonistic CD40 antibodies were shown to overcome T-cell tolerance in tumor-bearing mice and facilitate development of potent cytotoxic T-cell responses by enhancing the effects of cancer vaccines (8) (9) (10) (11) (12) . Recently, immune-modulatory regimens-cytokine therapy (1) (2) (3) (4) (5) (13) (14) (15) (16) (17) , radiotherapy (6, 7, (18) (19) (20) , chemotherapy (8) (9) (10) (11) (12) (21) (22) (23) , kinase inhibitors (24) , or monoclonal antibodies (25) -have been shown to synergize with agonistic CD40 antibodies, leading to tumor rejection in animal models.
However, systemic administration of immunostimulatory CD40 antibodies has been associated with cytokine release syndrome, lymphopenia, and liver toxicity in clinical trials (1, (3) (4) (5) . In preclinical models, Fransen and colleagues (6) observed that intravenous delivery of high-or low-dose agonistic CD40 antibody increased liver toxicity in mice bearing virally transformed tumors. Agonistic anti-CD40 biodistribution experiments by Sandin and colleagues (9) showed that systemic administration led to higher antibody concentrations in the liver compared with local delivery. However, the reason why systemic agonistic CD40 antibody causes liver toxicity remained unknown.
Tumor-induced myeloid-derived suppressor cells (MDSC) constitute one of the main players in tumor-induced immune suppression. They comprise a heterogeneous population of myeloid cells of diverse differentiation status, whose main feature is the suppression of innate and adaptive immune responses (8) . Our laboratory and others have previously described that tumor-induced CD11b þ Gr-1 þ MDSC accumulate in the liver of mice (13, 15, 17) and in patients with hepatocellular carcinoma (18, 20) . In addition, hepatic MDSC have been reported to promote the generation of liver metastasis (21) , and CD11b þ CCR2 þ cells have been detected in liver metastasis from patients with colorectal cancer (26) . However, little is known about the biology of tumor-induced hepatic MDSC.
In the study reported herein, we investigated the effect of agonistic anti-CD40 antibody injection on hepatic and splenic MDSC in tumor-bearing mice. Although agonistic anti-CD40 treatment led to severe, MDSC-mediated hepatitis in mice, we also provide evidence suggesting that MDSC mature into a proinflammatory cell type with less arginase activity. These results are recapitulated in human CD14
þ HLA-DR low MDSC, which also lose arginase expression and thereby suppressor function in vitro.
Materials and Methods

Mice and cell lines
Eight-to 10-week-old female BALB/c, C57BL/6-CD45.2, and BL6-CD45.1 were purchased from NCI/Frederick. H-2K b OVA 257-264 TCR transgenic OT-I, Cd40
À/À (purchased from The Jackson Laboratories), and Nox2 À/À mice (a kind gift from Robert Mumford, NCI) were bred at NCI/Frederick. Bone marrow chimeric mice were generated as previously described (27) . Bone marrow chimerism was confirmed 4 weeks after bone marrow transplant and was above 80%. EL4 and B16 GM-CSF cells were a kind gift of Dr. Drew Pardoll (The Johns Hopkins University, Baltimore, MD) and previously used (27) . 4T1 cells were kindly provided by Christopher A. Klebanoff (NCI). RIL-175 hepatocellular carcinoma cell line was obtained from Dr. Lars Zender (University Hospital of T€ ubingen, Germany) and used recently (13, 28) . All tumor cell lines used were tested negative for mycoplasma using a MycoAlert Plus kit (Lonza) routinely. Last test was performed on December 2014. Mice were injected subcutaneously in the flank with 1 Â 10 6 tumor cells. Tumor size was measured twice a week. Metastatic tumors were established in the liver by intrasplenic injection of 3 Â 10 5 EL4 cells (29) . Mice received antibody treatment 3 weeks after tumor cell inoculation into the spleen. All mice were handled, fed, and housed in accordance with the U.S. Department of Health and Human Services institutional guidelines.
In vivo antibody treatment
Tumor-free littermates or mice bearing subcutaneous tumors between 10 and 15 mm maximum diameter were inoculated i.p. with 100 mg of rat anti-mouse agonist CD40 antibody (clone FGK-45; BioXCell) or irrelevant rat IgG2a (2A3; BioXCell). Mice were sacrificed 24 hours after injection. Alanine/aspartate aminotransferase (ALT/AST) levels were determined in mouse sera by biochemistry analysis in the Department of Laboratory Medicine (NCI). Serum TNFa levels were quantified by ELISA following the manufacturer's instructions (eBioscience). Hematoxylin-eosinstained liver tissues were analyzed by a pathologist (D.E. Kleiner) in a blinded fashion.
Flow cytometry analysis
Liver mononuclear cells were obtained as previously described (13) . Mouse cell samples were stained using antibodies from BD Biosciences and eBioscience (available upon request). When indicated, tumor-induced hepatic myeloid cells were isolated using CD11b beads followed by magnetically activated cell separation (MACS) separation (Miltenyi Biotec). Purity after enrichment was above 90%. Flow cytometry was performed on BD FACS Calibur or LSRII using CellQuest Pro or FACS Diva acquisition software, respectively (Becton Dickinson). Data were analyzed using FlowJo software (Tree Star).
Functional assays in vitro
Reactive oxygen species (ROS) production was determined using Carboxy-H 2 DCFDA (Invitrogen) as described by Corzo and colleagues (30 þ HLA-DR low cells were purified as previously described (32) . When indicated, 1 Â 10 5 or 2 Â 10 5 sorted cells were cultured in complete RPMI medium with or without 0.1 mg/mL megaCD40L (Enzo Life Sciences) or 5 mg/mL anti-human CD40 antibody (clone 82111; R&D systems) for 24 hours. Then, total RNA was isolated using an RNeasy kit (Qiagen). cDNA synthesis was carried out using an iScript cDNA synthesis kit according to the manufacturer's instructions (Biorad). Arginase-1 qPCR (primer sequences available upon request) was performed using IQ SYBR Green Supermix and thermal cycler (Applied Biosystems). Triplicate reactions were performed for each sample, and expression of tested gene was normalized relative to levels of GAPDH. To assess human MDSC function, CD14 þ HLA-DR low cells were isolated from healthy donor PBMC and incubated at different ratios with CD3/CD28 (Miltenyi Biotec)-stimulated CD8 þ T cells previously isolated from the remaining CD14 À fraction (human CD8 þ T cell isolation kit; Miltenyi Biotec) in the presence or absence of 0.1 mg/mL megaCD40L. Proliferation was measured 72 hours later by incorporation of 3 H Thymidine (Amersham).
Statistical analysis
Analyses were performed with GraphPad Prism software. Data are provided as mean AE SEM, unless indicated otherwise. For comparisons between two groups, statistical analyses were performed using a Student t test, and P < 0.05 was considered significant. For comparisons involving three groups or more, a one-way ANOVA using the Kruskal-Wallis test was performed (P < 0.05 was considered statistically significant). When analyzing the response of two populations to two or more treatments, twoway ANOVA was performed (P < 0.05 was considered statistically significant). Symbols indicating statistical significance are as follows (unless indicated otherwise): n.s., not statistically significant; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.005.
Results
Systemic agonistic anti-CD40 induces immune-mediated acute hepatitis in tumor-bearing mice We treated na€ ve tumor-free and EL4 tumor-bearing mice with agonistic anti-CD40 or isotype IgG control. Systemic CD40 antibody treatment resulted in a significant increase of serum ALT and AST levels in tumor-bearing mice (ALT, 5,529 AE 647 U/L; AST, Fig. S1A and S1B). Histologic analysis of liver sections from EL4 tumor-bearing mice treated with agonistic anti-CD40 antibody showed signs of severe hepatitis with inflammatory cell infiltration and confluent parenchymal necrosis (Fig. 1C and D) . Similar results were obtained in 4T1 tumor-bearing BALB/c littermates ( Supplementary Fig. S1B and S1C). Furthermore, in a model of EL4-induced liver metastases ( Supplementary Fig. S2A ), systemic anti-CD40 agonist increased serum ALT and AST levels (ALT, 2,096 AE 759 U/L; AST, 5,645 AE 1,320 U/L) compared with IgG-treated mice (ALT, 414 AE 92 U/L; AST, 2,542 AE 619 U/L; Supplementary Fig. S2B ).
CD40 is not only expressed by liver-infiltrating immune cells but also by parenchymal cells such as hepatocytes (33) . Therefore, we generated Cd40 knockdown bone marrow chimeras to dissociate the relative contribution of the liver immune cell compartment to CD40 antibody-mediated liver damage from direct ligation of CD40 antibody on CD40-expressing hepatocytes. Transaminases were clearly elevated in EL4 tumor-bearing Fig. S1D ).
Agonistic CD40 antibody causes ROS-mediated hepatitis in tumor-bearing mice ROS produced by mononuclear phagocytes are important mediators of drug-induced hepatotoxicity (35) . We studied the role of ROS upon anti-CD40 treatment in tumor-bearing mice using phagocytic NADPH oxidase 2 (Nox2)-deficient mice. Lower transaminases were observed in EL4 tumor-bearing Nox2 (Fig. 2D) . To find out the contribution of hepatic myeloid cells in hepatocyte cell death, we isolated hepatic CD11b þ cells from tumor-bearing mice 3 hours after treatment either with agonistic anti-CD40 or isotype control and cocultured them with luciferase-expressing hepatoma cells. Using luciferase expression as readout of cell viability, luciferase signal was decreased when hepatoma cells were incubated with hepatic CD11b þ cells from agonistic anti-CD40-treated mice (Fig. 2E ).
CD11b þ -mediated cell death was blocked in the presence of the ROS inhibitor catalase, suggesting that CD40 ligation exacerbates ROS-mediated liver cell killing by tumor-induced hepatic myeloid cells. In summary, ROS release plays a role in systemic CD40 agonist-mediated hepatotoxicity.
Agonistic CD40 antibody modulates tumor-induced hepatic CD11b þ Gr-1 þ cells
Next, we studied CD11b þ Gr-1 þ cells after agonistic anti-CD40 treatment. We found that the absolute cell number of hepatic CD11b Apart from CD11b ( Supplementary Fig. S3C-S3G) . Interestingly, agonistic anti-CD40 treatment significantly increased the absolute number of CD40-and CD80-expressing CD11b Supplementary   Fig. S4 and Fig. 3B and C) . Similar results were observed in 4T1 BALB/c tumor-bearing mice ( Supplementary Fig. S3I and S3J ). To address whether the effects of agonistic anti-CD40 were restricted to hepatic myeloid cells or whether this was a systemic effect, we also studied splenic CD11b Gr-1 þ cells was also seen in spleens of tumor-bearing mice treated with agonistic anti-CD40 (Fig. 3D-F) . We further analyzed MDSC subsets and found that both hepatic G-MDSC and M-MDSC accumulated over time after anti-CD40 agonist injection ( Supplementary Fig. S5A and S5B) . However, hepatic G-MDSC produced more ROS than M-MDSC in response to CD40 ligation in vivo (Supplementary Fig. S5C ).
Finally, we studied the effects of agonistic anti-CD40 on hepatic CD11b þ cells in vitro. Here, a significant decrease in their arginase activity was seen upon anti-CD40 treatment (Fig. 3G) . Moreover, anti-CD40 treatment improved their ability to induce antigenspecific IFNg release by CD8 þ T cells (Fig. 3H) . Finally, significant levels of TNFa were detected in cell supernatants after incubation of tumor-induced hepatic myeloid cells with CD40 antibody (Fig. 3I) . In summary, CD40 ligation on tumor-induced hepatic myeloid cells results in enhanced maturation and activation in vivo and in vitro.
Tumor-induced hepatic CD11b cells mediate liver inflammation upon systemic agonistic CD40 antibody
To provide a direct link between the presence of hepatic myeloid cells and anti-CD40-mediated liver inflammation, we transferred WT tumor-induced hepatic CD45.1 where 80% were CD11b þ Gr-1 þ MDSC ( Supplementary Fig. S6A and S6B), into CD45.2 þ Cd40
À/À -na€ ve recipients followed by systemic injection of the agonistic anti-CD40. Although agonistic CD40 antibody did not cause inflammation to regular Cd40 À/À na€ ve mice, transfer of tumor-induced hepatic CD45.1 þ myeloid cells and subsequent agonistic anti-CD40 injection to the CD40 knockouts resulted in ALT and AST serum elevation ( Fig. 4A and  B) . In addition, an increase in TNFa serum levels was observed (Fig. 4C) . Consequently, CD40 ligation on tumor-induced hepatic myeloid cells resulted in enhanced inflammation. To address the role of myeloid-derived ROS in this setting, we transferred either WT or Nox2 À/À tumor-induced hepatic CD11b þ cells into tumor-induced hepatic CD11b þ cell transfer (Fig. 4C ).
CD40 ligation impairs immunosuppressive function of human CD14
þ HLA-DR low MDSC We isolated human CD14 þ HLA-DR low MDSC from PBMC of healthy controls (Fig. 5A) or patients (Fig. 5B ) with gastrointestinal cancer (Supplementary Table S1 ). CD40 engagement using multivalent CD40L reduced arginase-1 mRNA expression in I, TNFa from the cell culture supernatants was determined by ELISA. Data shown as mean AE SEM are representative of two independent experiments. n.s., not statistically significant; Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.005: (A-G, I) Student t test, (H) one-way ANOVA.
human CD14
þ HLA-DR low MDSC in both healthy controls and patients with cancer. This was not observed in CD14 þ HLA-DR high controls ( Fig. 5A and B) . Similar results were obtained using agonistic anti-human CD40 antibody (Supplementary Fig. S7 ). Next, we isolated CD14 þ HLA-DR low cells from PBMC and tested their suppressor function after CD40L treatment. CD40 ligation impaired the suppressor function of human CD14 þ HLA-DR low MDSC (Fig. 5C) . Interestingly, incubation of PBMC in the presence of CD40L resulted in enhanced ROS production by CD14 þ HLA-DR low cells (Fig. 5D ).
Discussion
The approval of ipilimumab by the FDA in 2011, and very recently pembrolizumab and nivolumab, has sparked great interest in immune checkpoint inhibitors in oncology in recent years (36) . Similarly, agonistic antibodies to TNF receptor molecules, such as activating CD137, OX40, and CD40 antibodies, have shown promising results in both preclinical and early clinical settings (5, 37, 38) . Different mechanisms of action have been described for agonistic anti-CD40 antibody therapy in cancer (37) . Here, we studied the effect of systemic anti-CD40 treatment in tumor-bearing mice on hepatic and splenic MDSC. We found that agonistic CD40 antibody triggered immune-mediated and ROS-dependent acute liver damage in tumor-bearing mice by activating hepatic CD11b (39) . Previously, transaminitis had been reported in patients treated with agonistic anti-CD40 in a phase I trial (1) . Similarly, liver toxicity upon agonistic anti-CD40 treatment has been observed in preclinical models upon intravenous administration, but this was reduced when the antibody was injected peritumorally (6). This adverse event was initially attributed to a direct effect of agonistic anti-CD40 on CD40-expressing hepatocytes (33) . Our findings suggest a potential alternative explanation, namely the engagement of hepatic CD11b þ Gr-1 þ MDSC and ultimately ROS release leading to hepatocyte death upon anti-CD40 treatment. There is a preferential accumulation of MDSC in the liver of tumor-bearing mice, which are in larger numbers than other myeloid populations such as Kupffer cells (13, 15, 17, 28) . These cells express low levels of CD40 (40) (41) (42) , which can be further enhanced upon incubation with IFNg (43) as well as in a setting of acute inflammation (data not shown). Our data using bone marrow chimeric mice clearly suggest a pivotal role for CD40-expressing myeloid cells in CD40-mediated liver damage in tumor-bearing mice. First, serum transaminases and TNFa serum levels were higher in Cd40 À/À mice reconstituted with WT bone marrow than in WT mice after reconstitution with Cd40 À/À bone marrow. Second, adoptive transfer of WT MDSC into Cd40 À/À mice followed by agonistic anti-CD40 treatment resulted in increased transaminases and TNFa serum levels. Oxidative stress via ROS release by mononuclear phagocytes plays a pivotal role in inflammatory liver injury (35) . Treatment of mice with free radical scavengers decreased ALT in a model of immune-mediated hepatitis (44) . Using phagocytic Nox2-deficient mice to study the potential contribution of ROS (30) in agonistic CD40 antibody-mediated liver damage, we observed that knockout tumor-bearing mice had lower ALT/ AST levels than tumor-bearing littermate controls, suggesting a ROS-mediated liver cell damage in our model. We provide further biologic evidence by showing that tumor-induced hepatic myeloid cells produce ROS upon CD40 ligation, which in turn induces hepatocyte cell death.
Our data show that systemic administration of agonistic anti-CD40 increased the accumulation of CD11b þ Gr-1 þ cells in the liver of tumor-bearing mice. Our experiments did not address a possible role for liver-infiltrating neutrophils, which accumulate in murine models of immune-mediated hepatitis by margination of neutrophils through sinusoids (45) . Inflammatory neutrophils express CD11b and high levels of Gr-1 similar to the granulocytic subset of tumor-induced hepatic MDSC. However, we provide multiple lines of evidence suggesting that tumor-induced hepatic CD11b Our data suggest that tumor-induced hepatic and-to a lesser extent-splenic CD11b (18) (19) (20) 49) . Although an accumulation of CD11b þ CCR2 þ cells has been described in sections obtained from patients with colorectal liver metastasis (22, 23, 26) , it is not known so far whether MDSC also accumulate in tumor-free livers of patients with cancer. Therefore, at this point, one can only speculate whether hepatic MDSC caused ALT/AST elevations in patients treated with agonistic anti-CD40, and further studies are clearly needed.
Tumor-induced mouse myeloid cells and human CD14 þ HLA-DR low MDSC both express high arginase levels and can suppress T-cell function through an arginase-dependent mechanism (24, 50) . Both our murine and human data clearly suggest that agonistic anti-CD40 treatment may impair the suppressor function of MDSC and would therefore represent a potential novel approach to target MDSC as also recently suggested by others (25, 51) .
Immune-related adverse effects in clinical trials have been associated with the systemic use of immune-modulatory drugs (5) . Much of anti-CD40 treatment-dependent toxicity can be avoided by local delivery in a slow-release vehicle, maintaining its antitumor effects in animal models (6, 9) . However, it is not clear whether such treatment would also induce MDSC maturation. Therefore, further studies are needed to investigate new administration routes and compounds to stabilize and prolong the effect of immune-modulatory compounds with the aim to mitigate immunotherapy-related toxicity and potentially target MDSC.
Overall, our data indicate that liver toxicity caused by systemic CD40 antibody in mice is due to activation of tumor-induced hepatic CD11b 
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